Researchers from Massachusetts General Hospital and affiliated organizations have published preclinical data for [18F]CNL-02, a positron emission tomography (PET) radioligand targeting mitochondrial complex I (MC-I) that is being developed for the diagnosis of Alzheimer’s disease and other neurodegenerative disorders.
Researchers from Astrazeneca plc and Karolinska Institutet have described the positron emission tomography (PET) evaluation of [11C]AZD-2423, a chemokine receptor type 2 (CCR2) radioligand in non-human primate (NHP) brain imaging. CCR2 is essential in immune cell migration control. It is mainly expressed in microglia and monocytes and closely linked to the brain’s immune defense.
Mesenchymal-epithelial transition factor (MET) plays a relevant role in growth, survival, migration and tissue repair. Alterations in MET have been found in non-small-cell lung cancer and head and neck cancer, and are associated with aggressive and difficult-to-treat cancer types.
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to assess the levels of 5,400 different proteins.
Work at Beijing Normal University and affiliated organizations has led to the discovery and preclinical characterization of a novel tau-PET radiotracer for Alzheimer’s disease (AD).
Artificial intelligence (AI)-based models developed by a team of international researchers were able to identify ovarian cancer in ultrasound images more accurately than humans. Results from a study published in Nature Medicine showed that the AI models achieved an accuracy rate of 86.3%, compared to 82.6% for the experts and 77.7% for the non-expert examiners.
In a recently published study, researchers from the University of Pennsylvania and collaborators aimed to identify compounds with high affinity to α-synuclein aggregates and high selectivity toward pathological α-synuclein compared to other brain targets.
Peptidream Inc. has announced a new peptide radiopharmaceutical development candidate, PD-29875, a novel first-in-class highly selective macrocyclic peptide-radioisotope conjugate against Claudin 18.2 (CLDN18.2).
Researchers at Stichting AMC Foundation and Vrije Universiteit van Amsterdam have identified [18F]-labeled pyrazolidine-3,5-dione compounds targeting P2Y purinoceptor 12 (P2RY12; P2Y12) acting as PET and SPECT imaging agents. They are reported to be useful for the diagnosis of multiple sclerosis, Alzheimer’s disease and Parkinson’s disease.
Telix Pharmaceuticals Ltd. is expanding its theranostic pipeline with new assets targeting fibroblast activation protein (FAP). The company has entered into asset purchase and exclusive worldwide in-license agreements for a suite of clinically validated FAP-targeting therapeutic and precision medicine (diagnostic) radiopharmaceutical candidates developed at Johannes Gutenberg-Universität Mainz.
RSS
